S'abonner

A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study - 06/08/11

Doi : 10.1503/cmaj.090533 
Julie Villeneuve, PhD, Jacques Genest, MD, Lucie Blais, PhD, Marie-Claude Vanier, MSc, Diane Lamarre, MSc, Marc Fredette, PhD, Marie-Thérèse Lussier, MD, Sylvie Perreault, PhD, Eveline Hudon, MD, Djamal Berbiche, PhD, Lyne Lalonde, PhD
From the Faculties of Pharmacy (Villeneuve, Blais, Vanier, Lamarre, Perreault, Lalonde) and of Medicine (Lussier, Hudon), Université de Montréal, Montréal, Que.; the Research Team in Primary Care (Villeneuve, Vanier, Lussier, Hudon, Berbiche, Lalonde) and Hôpital de la Cité-de-la-Santé (Vanier), Centre de santé et de services sociaux de Laval, Laval, Que.; Sanofi-Aventis Canada Inc. (Villeneuve), Laval, Que.; the Department of Cardiology (Genest), McGill University Health Centre, Royal Victoria Hospital, Montréal, Que.; Ordre des pharmaciens du Québec (Lamarre), Montréal, Que.; and the Department of Management Sciences (Fredette), École des hautes études commerciales de Montréal, Montréal, Que 

*Correspondence to: Dr. Lyne Lalonde, Research Team in Primary Care, Centre de santé et de services sociaux de Laval, Hôpital de la Cité-de-la-Santé, 1755 René-Laennec Blvd., Rm. D-S080, Laval QC H7M 3L9

Contributors: Lyne Lalonde, Julie Villeneuve, Jacques Genest, Lucie Blais, Marie-Claude Vanier, Diane Lamarre, Marie-Thérèse Lussier, Sylvie Perreault and Eveline Hudon contributed substantially to the conception and design of the study protocol; Julie Villeneuve and Lyne Lalonde contributed to the acquisition of data; and Julie Villeneuve, Lyne Lalonde, Lucie Blais, Djamal Berbiche and Marc Fredette were responsible for the data analysis. As principal investigator, Lyne Lalonde was responsible for writing the study protocol and this paper, as well as supervising the conduct of the study and the statistical analyses. All of the authors critically revised the article and gave final approval for the version submitted.

Abstract

Background

Few studies have reported the efficacy of collaborative care involving family physicians and community pharmacists for patients with dyslipidemia.

Methods

We randomly assigned clusters consisting of at least two physicians and at least four pharmacists to provide collaborative care or usual care. Under the collaborative care model, pharmacists counselled patients about their medications, requested laboratory tests, monitored the effectiveness and safety of medications and patients’ adherence to therapy, and adjusted medication dosages. After 12 months of follow-up, we assessed changes in low-density lipoprotein (LDL) cholesterol (the primary outcome), the proportion of patients reaching their target lipid levels and changes in other risk factors.

Results

Fifteen clusters representing a total of 77 physicians and 108 pharmacists were initially recruited, and a total of 51 physicians and 49 pharmacists were included in the final analyses. The collaborative care teams followed a total of 108 patients, and the usual care teams followed a total of 117 patients. At baseline, mean LDL cholesterol level was higher in the collaborative care group (3.5 v. 3.2 mmol/L, p = 0.05). During the study, patients in the collaborative care group were less likely to receive high-potency statins (11% v. 40%), had more visits with health care professionals and more laboratory tests, were more likely to have their lipid-lowering treatment changed and were more likely to report lifestyle changes. At 12 months, the crude incremental mean reduction in LDL cholesterol in the collaborative care group was −0.2 mmol/L (95% confidence interval [CI] −0.3 to −0.1), and the adjusted reduction was −0.05 (95% CI −0.3 to 0.2). The crude relative risk of achieving lipid targets for patients in the collaborative care group was 1.10 (95% CI 0.95 to 1.26), and the adjusted relative risk was 1.16 (95% CI 1.01 to 1.34).

Interpretation

Collaborative care involving physicians and pharmacists had no significant clinical impact on lipid control in patients with dyslipidemia. International Standard Randomized Controlled Trial register no. ISRCTN66345533.

Le texte complet de cet article est disponible en PDF.

Plan


 Previously published at www.cmaj.ca
This article has been peer reviewed.
Competing interests: Marie-Thérèse Lussier is the principal investigator for a research project funded by AstraZeneca Canada. She has received educational grants for adaptation and translation of patient communication papers from Merck, AstraZeneca and Sanofi. She received sponsorship from AstraZeneca to attend the European Association for Communication in Health Care (EACH) meeting in September 2008. None declared for all other authors.
Funding: This research was funded by a grant from the Canadian Institutes of Health Research(grant number 200409MCT-133732-RCT) and unrestricted research grants from AstraZeneca Canada Inc., Merck Frosst Canada Ltd. and Pfizer Canada Inc. Research scholars Lyne Lalonde, Lucie Blais and Sylvie Perreault received financial support from the Fonds de la recherche en santé du Québec.


© 2010  Canadian Medical Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 182 - N° 5

P. 447-455 - mars 2010 Retour au numéro
Article précédent Article précédent
  • Urinary tract abnormalities in Chinese rural children who consumed melamine-contaminated dairy products: a population-based screening and follow-up study
  • Jian-meng Liu, Aiguo Ren, Lei Yang, Jinji Gao, Lijun Pei, Rongwei Ye, Quangang Qu, Xiaoying Zheng
| Article suivant Article suivant
  • How can delirium best be prevented and managed in older patients in hospital?
  • Jayna M. Holroyd-Leduc, Farah Khandwala, Kaycee M. Sink

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.